Annual report pursuant to Section 13 and 15(d)

Notes Payable (Details)

Notes Payable (Details) (USD $)	1 Months Ended	12 Months Ended			0 Months Ended	1 Months Ended	12 Months Ended	1 Months Ended	0 Months Ended	3 Months Ended	6 Months Ended		1 Months Ended
Notes Payable (Details) (USD $)	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jul. 15, 2014	Jun. 30, 2013	Dec. 31, 2011	Dec. 31, 2011 installment	Jun. 25, 2013	Mar. 31, 2012	Jun. 24, 2013	Jun. 25, 2013	Mar. 31, 2014	Jul. 31, 2012	Mar. 04, 2014
Notes Payable [Line Items]
Warrants, exercise price		$ 2.27
Debt instrument, debt discount		$ 829,019	$ 743,062
Repayments of notes payable		25,000,000us-gaap_RepaymentsOfNotesPayable	5,982,155us-gaap_RepaymentsOfNotesPayable	1,285,046us-gaap_RepaymentsOfNotesPayable
Loss on extinguishment of debt		2,610,196	1,372,266	0
Debt committed upon the approval of Lymphoseek on consistent terms	20,000,000
Interest rate stated percentage				2.80%
Change in fair value of financial instruments		(1,342,389)	(112,073)	32,110
Interest expense related to debt		3,700,000us-gaap_InterestExpenseDebt	2,800,000us-gaap_InterestExpenseDebt	1,200,000us-gaap_InterestExpenseDebt
Non-cash interest expense related to debt		844,000	765,000	545,000
Principal maturities in 2015		5,200,000
Principal maturities in 2016		7,300,000
Principal maturities in 2017		7,600,000
Principal maturities in 2018		8,300,000
Principal maturities in 2019		5,400,000
R-NAV [Member]
Notes Payable [Line Items]
Promissory note payable					666,666
Federal Funds Rate [Member] \| R-NAV [Member]
Notes Payable [Line Items]
Debt instrument, spread on variable rate					0.31%
Common Stock [Member]
Notes Payable [Line Items]
Number of common shares underlying Series B Preferred Stock		14,777,130
Shares conversion, number of common stock equivalent to each preferred stock		3,270				3,270
Series B Preferred Stock [Member]
Notes Payable [Line Items]
Conversion of Series B preferred stock to common stock, shares			2,364.9			2,364.9
Series GG Warrants [Member]
Notes Payable [Line Items]
Warrants, exercise price		$ 2.10
Warrants, expiration date		Dec. 29, 2016
Derivative liabilities							520,478	520,478
Provision effective period							0 years 0 months 365 days
Series HH Warrants [Member]
Notes Payable [Line Items]
Warrants, number of securities called by warrants						301,205
Warrants, exercise price		$ 2.49
Warrants, expiration date		Jun. 25, 2023
Hercules Secured Term Promissory Note [Member]
Notes Payable [Line Items]
Current borrowing capacity							7,000,000	7,000,000
Debt instrument, spread on variable rate								6.75%
Debt Instrument, minimum effective interest rate								10.00%
Monthly installments								30
Debt instrument, frequency of payment								monthly
Debt conversion, original debt, amount convertible								1,500,000
Beneficial conversion feature								24,888
Debt issuance costs								593,339
Debt instrument, debt discount							545,366	545,366
Hercules Secured Term Promissory Note [Member] \| Series GG Warrants [Member]
Notes Payable [Line Items]
Warrants, number of securities called by warrants							333,333	333,333
Warrants, exercise price							$ 2.10	$ 2.10
Warrants, expiration date								Dec. 31, 2016
Hercules Technology Ii Lp Notes [Member]
Notes Payable [Line Items]
Debt instrument, debt discount									187,000			187,000
Repayments of notes payable									4,400,000	1,300,000	1,300,000
Debt instrument, end of term fee									250,000
Debt instrument, early payment penalty									66,000			66,000
Loss on extinguishment of debt												429,000
Unamortized debt issuance expense									176,000			176,000
Platinum Montaur Life Sciences Llc Credit Facility [Member]
Notes Payable [Line Items]
Maximum borrowing capacity		35,000,000
Debt instrument, spread on variable rate		6.75%
Repayments of notes payable			4,800,000			4,781,333
Interest rate stated percentage		10.00%
Interest rate in addition to amended agreement		0.125%
Percentage of VWAP for conversion calculation		90.00%
Number of days preceding the date of conversion request		10 days
Minimum revenue from sales and licensing for mandatory repayment due		2,000,000
Warrants not settleable in cash fair value									943,000			943,000
Platinum notes payable		5,600,000
Change in fair value of financial instruments			106,000
Notes payable		3,200,000
Remaining borrowing capacity		31,800,000
Platinum Montaur Life Sciences Llc Credit Facility [Member] \| Series X Warrants And Series AA Warrants [Member]
Notes Payable [Line Items]
Number of common shares underlying Series B Preferred Stock		7,733,223				7,733,223
Second Amended Platinum Note [Member]
Notes Payable [Line Items]
Interest rate stated percentage rate range minimum													10.00%
Debt instrument, effective interest rate		10.00%
Second Amended Platinum Note [Member] \| Base Rate [Member]
Notes Payable [Line Items]
Debt instrument, spread on variable rate													6.75%
Second Amended Platinum Note [Member] \| Oxford Loan Agreement, Interest Rate [Member]
Notes Payable [Line Items]
Debt instrument, spread on variable rate													0.125%
General Electric Capital Corporation [Member]
Notes Payable [Line Items]
Debt issuance costs		120,000	881,000
End-of-term fee amount									2,400,000			2,400,000
General Electric Capital Corporation [Member] \| Series HH Warrants [Member]
Notes Payable [Line Items]
Warrants, exercise price						2.49
GECC, MidCap Financial SBIC and LP (MidCap) [Member]
Notes Payable [Line Items]
Debt instrument, frequency of payment						monthly
Debt issuance costs												881,000
Debt instrument, debt discount									1,900,000			1,900,000
Loss on extinguishment of debt		2,600,000
Debt instrument, effective interest rate									9.83%			9.83%
Debt instrument face amount									25,000,000			25,000,000
Debt instrument, number of periodic installments						30
Percentage of original principal amount of loan to be paid as a fee												4.00%
Repayments of long-term debt													26,700,000
Early redemption fee amount															500,000
End-of-term fee amount									1,000,000			1,000,000			1,000,000
GECC, MidCap Financial SBIC and LP (MidCap) [Member] \| Series HH Warrants [Member]
Notes Payable [Line Items]
Warrants, number of securities called by warrants									301,205			301,205
Warrants, exercise price									$ 2.49			$ 2.49
Oxford Finance, LLC [Member]
Notes Payable [Line Items]
Debt issuance costs													120,000
Debt instrument, debt discount		2,400,000
Interest rate stated percentage															8.50%
Notes payable		30,000,000
Debt instrument face amount															30,000,000
Debt instrument term		48 months
Final payment multiplier percent		7.95%
Unamortized discount (premium), net															3,000,000
Deferred finance costs net		90,000
Series KK Warrants [Member] \| Oxford Finance, LLC [Member]
Notes Payable [Line Items]
Warrants, number of securities called by warrants															391,032
Warrants, exercise price															$ 1.918
Hercules Loan and Security Agreement [Member]
Notes Payable [Line Items]
Debt instrument, spread on variable rate														0.125%
Platinum Credit Facility [Member]
Notes Payable [Line Items]
Maximum borrowing capacity														50,000,000
Current borrowing capacity														15,000,000
Debt instrument, spread on variable rate														6.75%
Debt Instrument, minimum effective interest rate														10.00%
Amount potentially available on terms to be negotiated	15,000,000
Proceeds from lines of credit			4,000,000	4,000,000
Significant Unobservable Inputs (Level 3) [Member] \| Platinum Montaur Life Sciences Llc Credit Facility [Member]
Notes Payable [Line Items]
Change in fair value of financial instruments		$ 1,348,000